8-K filing — Silo Pharma, Inc. (SILO)
Filed: 2026-10-14 AccNo: 0001213900-26-109457 Size: 236 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Filings · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-14 AccNo: 0001213900-26-109457 Size: 236 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
On October 1, 2026, Silo Pharma, Inc. (the "Company") entered into an asset purchase agreement (the "Agreement") with Norsight Consulting Inc., an Arkansas corporation (the "Seller"). Pursuant to